|
GB201105751D0
|
|
G-quadruplex stabilising agent
|
|
GB201011602D0
|
|
Delivery of hydrophilic peptides
|
|
GB201000737D0
|
|
Dendrimers
|
|
GB0919823D0
|
|
Hydrophobic drug complexes
|
|
GB0903559D0
|
|
Oral delivery of hydrophilic drugs to the brain
|
|
GB0723439D0
|
|
Naphthalene diimide compounds
|
|
GB0718023D0
|
|
Anti-bacterial agents
|
|
GB0715752D0
|
|
Nanovesticles for therapuetic and cosmetic use
|
|
GB0706932D0
|
|
Ureylene derivatives
|
|
GB0623492D0
|
|
Therapeutic G-quadruplex ligands
|
|
GB0621707D0
|
|
Formulations for delivery via pressurised metered dose inhalers
|
|
GB0607534D0
|
|
Colonic drug delivery formulation
|
|
WO2006003458A1
|
|
Pyrans for use in the treatment of infection
|
|
GB0506446D0
|
|
Container closing apparatus
|
|
GB0505779D0
|
|
Drug release system
|
|
GB0505644D0
|
|
Analogues of the azinomycins as anti-tumour agents and as prodrugs
|
|
GB0502790D0
|
|
Solid dispersion of hydrophobic bioactive
|
|
WO2005061453A1
|
|
Antharquinone compounds as anti cancer compounds
|
|
GB0418141D0
|
|
Method of producing microparticles
|
|
GB0415576D0
|
|
Colonic drug delivery dosage form
|
